US 11,891,393 B2
Functionalized heterocycles as antiviral agents
Joseph Panarese, Newton, MA (US); Dexter Davis, Watertown, MA (US); Samuel Bartlett, Brighton, MA (US); Katherine Chong, Belmont, MA (US); Nathaniel Kenton, Watertown, MA (US); and Yat Sun Or, Waltham, MA (US)
Assigned to Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed by Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed on Nov. 3, 2021, as Appl. No. 17/517,740.
Application 17/517,740 is a continuation of application No. 16/689,448, filed on Nov. 20, 2019, granted, now 11,198,693.
Claims priority of provisional application 62/884,486, filed on Aug. 8, 2019.
Claims priority of provisional application 62/770,428, filed on Nov. 21, 2018.
Prior Publication US 2023/0075366 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/14 (2006.01); A61K 31/4985 (2006.01); A61K 45/06 (2006.01)
CPC C07D 471/14 (2013.01) [A61K 45/06 (2013.01)] 20 Claims
 
1. A compound represented by Formula (XII-3) or Formula (XII-6), or a pharmaceutically acceptable salt or ester thereof:

OG Complex Work Unit Chemistry
wherein
Y1 is hydrogen or fluorine;
R1 is optionally substituted aryl or optionally substituted heteroaryl; and
R2 is hydrogen, optionally substituted C3-C6-cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl.